withdrawn claims Fernandez-Salas, E., et al., Botulinum Toxin Screening Assays

are herein rejoined. /vgp/

AMENDMENTS

Amendments to the Claims

- (Currently amended) A <u>cell-based</u> method of detecting BoNT/A activity the <u>method</u> comprising the steps of:-by
 - a) contacting a sample to a cell-that contains comprising an exogenous FGFR3 and an endogenous SNAP-25, wherein said contacted cell is capable of BoNT/A intoxication and
 - b) detecting the presence of BoNT/A activity of said contacted cell relative to a control cell, wherein-a difference in the presence of endogenous SNAP-25 cleavage product from-said BoNT/A activity of said contacted cell-as-compared to said control-cell is indicative of BoNT/A activity.
- (Withdrawal) The method according to Claim 1, wherein said cell transiently contains an exogenous FGFR3.
- (Withdrawal) The method according to Claim 1, wherein said cell stably contains an exogenous FGFR3.
- 4. (Original) The method according to Claim 1, wherein said FGFR3 is a mammalian FGFR3.
- (Previously presented) The method according to Claim 4, wherein said mammalian FGFR3 is a human FGFR3.
- (Previously presented) The method according to Claim 4, wherein said mammalian FGFR3 is a bovine FGFR3
- (Previously presented) The method according to Claim 4, wherein said mammalian FGFR3 is a mouse FGFR3.
- (Previously presented) The method according to Claim 4, wherein said mammalian FGFR3 is a rat FGFR3

9. (Withdrawal) The method according to Claim 1, wherein said FGFR3 is a bird FGFR3.

- 10. (Withdrawal) The method according to Claim 9, wherein said bird FGFR3 is a chicken
- FGFR3.
- 11. (Withdrawal) The method according to Claim 1, wherein said FGFR3 is an amphibian FGFR3.
- 12. (Withdrawal) The method according to Claim 11, wherein said amphibian FGFR3 is a frog FGFR3
- 13. (Withdrawal) The method according to Claim 11, wherein said amphibian FGFR3 is a newt FGFR3.
- 14. (Withdrawel) The method according to Claim 1, wherein said FGFR3 is a fish FGFR3.
- 15. (Withdrawal) The method according to Claim 16, wherein said fish FGFR3 is a zebrafish FGFR3.
- 16. (Original) The method according to Claim 1, wherein said cell further contains a G1b polysialoganglioside.
- 17. (Original) The method according to Claim 16, wherein said polysialoganglioside is selected from the group consisting of GD1a, GD1b, GD3, GQ1b, or GT1b.
- 18. (Original) The method according to Claim 1, wherein said cell is a neuronal cell.
- 19. (Original) The method according to Claim 18. wherein said neuronal cell is a primary neuronal cell.
- 20. (Original) The method according to Claim 18, wherein said neuronal cell is an immortalized neuronal cell.

Application No.: 10/598.073 Fernandez-Salas, E., et al., Botulinum Toxin Screening Assavs

21. (Original) The method according to Claim 18, wherein said neuronal cell is a transformed neuronal cell.

- 22. (Original) The method according to Claim 18, wherein said neuronal cell is selected from the group consisting of a neuroblastoma cell, a neuronal hybrid cell, a spinal cord cell, a central nervous system cell, a cerebral cortex cell, a dorsal root ganglion cell, a hippocampal cell and a pheochromocytoma cell.
- 23. (Withdrawal) The method according to Claim 1, wherein said cell is a non-neuronal cell.
- 24. (Withdrawal) The method according to Claim 23, wherein said non-neuronal cell is a primary neuronal cell.
- 25. (Withdrawal)- The method according to Claim 23, wherein said non-neuronal cell is an immortalized neuronal cell.
- 26. (Withdrawal). The method according to Claim 23, wherein said non-neuronal cell is a transformed neuronal cell.
- 27. (Withdrawal). The method according to Claim 23, wherein said non-neuronal cell is selected from the group consisting of an anterior pituitary cell, an adrenal cell, a pancreatic cell, an ovarian cell, a kidney cell, a stomach cell, a blood cell, an epithelial cell, a fibroblast, a thyroid cell, a chondrocyte, a muscle cell, a hepatocyte, a glandular cell.
- 28. (Original) The method according to Claim 1, wherein said sample is selected from the group consisting of a purified BoNT/A, a partially purified BoNT/A or unpurified BoNT/A.
- 29. (Original) The method according to Claim 1, wherein said sample is selected from the group consisting of a bulk BoNT/A, a formulated BoNT/A, a cosmetics BoNT/A formulation or a clinical BoNT/A formulation.
- 30. (Original) The method according to Claim 1, wherein said sample is a recombinant BoNT/A.

Fernandez-Salas, E., et al., Botulinum Toxin Screening Assays

- 31. (Original) The method according to Claim 1, wherein said sample is selected from the group consisting of a raw food, a cooked food, a partially cooked food or a processed food.
- 32. (Original) The method according to Claim 1, wherein said sample is a sample taken from a mammal.
- 33. (Original) The method according to Claim 32, wherein said mammalian sample is selected from the group consisting of a tissue, a saliva, an excretion or a feces.
- 34-78. (Canceled).